# US 10,246,511 B2 · Fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,246,511 B2
- Document ID: US10246511B2
- Status: Granted
- Kind: B2
- Application number: 15/667,424
- Filed: 2017-08-02
- Published: 2017-11-30
- Granted: 2019-04-02
- Earliest claimed: 2013-07-19
- Assignees: Samsung Electronics Co., Ltd.
- Applicants: Samsung Electronics Co., Ltd.
- Inventors: Kwang Hoon Lee; Hyung-Chan Kim; Sang Yeul Han; Seok Kyun Kim; Kyung Eun Kim
- Web page: https://patentgrep.com/patent/US10246511B2

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/71: for growth factors; for growth regulators
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.

## Claims

### Claim 1

A fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D, comprising a VEGFR2 extracellular domain, a VEGFR3 extracellular domain, and the Fc region of an immunoglobulin, wherein the VEGFR2 extracellular domain comprises Ig-like domain 2, and the VEGFR3 extracellular domain comprises Ig-like domain 2.

### Claim 2 (depends on 1)

The fusion polypeptide according to claim 1, wherein the fusion polypeptide comprises a VEGFR2 extracellular domain comprising amino acid residues 120-220 of SEQ ID NO: 2, a VEGFR3 extracellular domain comprising amino acid residues 136-226 of SEQ ID NO: 3, and the Fc region of an immunoglobulin.

### Claim 3 (depends on 1)

The fusion polypeptide according to claim 1, wherein the fusion polypeptide comprises a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4, and the Fc region of immunoglobulin.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the fusion polypeptide of claim 1.

### Claim 5 (depends on 1)

A method for treating a neovascular disease, inhibiting angiogenesis or lymphangiogenesis, or inhibiting proliferation and metastasis of cancer, comprising administering a therapeutically effective amount of the fusion polypeptide of claim 1 to a subject in need thereof.